Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

NCT05110742 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Hematological Malignancy

Interventions

DRUG: Fludarabine Phosphate
DRUG: Cyclophosphamide
DRUG: CAR.5/IL15-transduced CB-NK cells

Sponsor

M.D. Anderson Cancer Center